Author

Maria Harrie

Observed names: M Harrie, M. Harrie

Institution: Camurus AB (Sweden)

Observed institutions: Iowa State University, Camurus AB (Sweden), Auburn University

OpenAlex ID: A5113201838

Octreotide Subcutaneous Depot for Acromegaly: A Randomized, Double-blind, Placebo-controlled Phase 3 Trial, ACROINNOVA 1

2024 · Diego Ferone, Pamela Freda, et al. · The Journal of Clinical Endocrinology & Metabolism · 26

Immunolocalization of the hyaluronan receptor CD44 in the reproductive tract of the mare

2010 · I. Rodriguez Hurtado, A.J. Stewart, et al. · Theriogenology · 14

7373 CAM2029, Octreotide Subcutaneous Depot, Provides Sustained Biochemical Control of Acromegaly: Interim Results From a Phase 3 Study (ACROINNOVA 2)

2024 · D Ferone, J Silverstein, et al. · Journal of the Endocrine Society · 3

7376 Efficacy and Safety of CAM2029 in Patients With Controlled or Inadequately Controlled Acromegaly on Standard-of-Care Treatment: Interim Data for the “New to CAM2029” Patient Subgroup in a Phase 3 Study (ACROINNOVA 2)

2024 · D Ferone, J L Spencer-Segal, et al. · Journal of the Endocrine Society · 1

An open-label long-term Phase 3 study of CAM2029 in patients with acromegaly (ACROINNOVA 2): interim analysis of the subgroup of patients 'new to CAM2029' with controlled or uncontrolled acromegaly on standard-of-care treatment

2024 · Diego Ferone, Spencer-Segal Joanna L., et al. · Endocrine Abstracts · 1

An open-label long-term Phase 3 study of CAM2029, an octreotide subcutaneous depot, in patients with acromegaly (ACROINNOVA 2): interim analysis of the ACROINNOVA 1 roll-over patients subgroup

2024 · Diego Ferone, Julie Silverstein, et al. · Endocrine Abstracts · 1

THU070 Randomized, Placebo-controlled Phase 3 Trial Protocol Assessing The Efficacy And Safety Of Octreotide Subcutaneous Depot (CAM2029) In Patients With Acromegaly

2023 · Diego Ferone, Pamela Freda, et al. · Journal of the Endocrine Society · 1

P266 - ECE_1022 - Long-term safety, biochemical control and symptom management with CAM2029 in the 52-week ACROINNOVA 2 open-label extension

2026 · Diego Ferone, Beverly M K Biller, et al. · European Journal of Endocrinology

RC3.4 - ECE_1029 - Effect of CAM2029 on long-term biochemical and symptom control in patients with acromegaly according to prior injectable somatostatin receptor ligand

2026 · Maria Fleseriu, Irina Bancos, et al. · European Journal of Endocrinology

Long-term and sustained biochemical control of acromegaly and improved quality of life with CAM2029 octreotide subcutaneous depot: final analysis of the core phase of ACROINNOVA 2

2026 · Robert D. Murray, Harpal S. Randeva, et al. · Endocrine Abstracts

Results from the core phase of the open-label, phase 3 ACROINNOVA 2 trial: CAM2029, a subcutaneous octreotide depot, achieves sustained, long-term biochemical control in acromegaly

2025 · Joanna L. Spencer-Segal, Julie M. Silverstein, et al. · Endocrine Abstracts

CAM2029, a self-administered subcutaneous octreotide depot, improved pros and symptoms in patients with ACROMEGALY in the acroinnova 2 phase 3 trial: final analysis of the core phase results

2025 · Diego Ferone, Biller Beverly M.K., et al. · Endocrine Abstracts

7377 CAM2029, Octreotide Subcutaneous Depot, Improves Patient-Reported Outcomes From Standard-of-Care Baseline in Patients With Acromegaly: Interim Results From a Phase 3 Study (ACROINNOVA 2)

2024 · Diego Ferone, Pietro Maffei, et al. · Journal of the Endocrine Society

A randomised phase 3 trial to assess efficacy and safety of CAM2029, an octreotide subcutaneous depot, in patients with acromegaly

2024 · Diego Ferone, Julie Silverstein, et al. · Endocrine Abstracts

An open-label long-term Phase 3 study of CAM2029, an octreotide subcutaneous depot, in patients with acromegaly (ACROINNOVA 2): interim analysis of patient-reported outcomes

2024 · Diego Ferone, Pietro Maffei, et al. · Endocrine Abstracts

#1705024 A Randomized Phase 3 Trial to Assess Efficacy and Safety of a Novel Formulation of Octreotide Subcutaneous Depot (CAM2029) in Patients With Acromegaly

2024 · Julie Silverstein, Julie Silverstein, et al. · Endocrine Practice

Works count: 18

Citation count: 48

H-index: 3

I10-index: 2